arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Amylyx Pharmaceuticals, Inc.

AMLX
$30.59 ▼ -2.38 (-7.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Amylyx Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -15.1% ↘
FCF / Share $-0.28 ↗
Trailing P/E —
Price / Book 14.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↑ +100.0% —
Net Income Profit after all expenses
$-41.28M
↓ -15.0% —
Operating Margin Operating profit as % of sales
-137.8%
↓ -7825.9% —
FCF / Share Free cash flow per share
$-0.28
↑ +15.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 23 quarters